Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and CD3. Linclatamig can bind to LY6G6D and CD3-positive T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in tumor research[1].
Molecular Weight:
(145.72 kDa)
Purity:
96.09
CAS Number:
[2885203-43-8]
Target:
CD3
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted